Loading
NASDAQHealthcareBiotechnology
Latest quote
$18.66
−$0.50 · -2.61%
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Regular session
$18.66
−$0.50 · -2.61%
Regular session · ET · Market data may be delayed.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Day range
Current $18.66
52-week range
Current $18.66
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
34
Expensive
Sentiment
69
Bullish
Risk
37
Moderate Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Day range
Current $18.66
52-week range
Current $18.66
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 330.53M USD | 108.46M USD | 48.66M USD |
| Cost of goods sold | 11.18M USD | — | — | — | — |
| Gross profit | −11.18M USD | — | 330.53M USD | 108.46M USD | 48.66M USD |
| Research and development | 418.78M USD | 396.44M USD | 423.88M USD | 358.73M USD | 265.35M USD |
| Selling, general, and administrative | 97.1M USD | 105.44M USD | 103.35M USD | 90.48M USD | 79.06M USD |
| Operating expenses | 544.16M USD | 487.34M USD | 527.23M USD | 449.21M USD | 344.41M USD |
| Interest income | 42.9M USD | 64.64M USD | 51.51M USD | 14.77M USD | 4.6M USD |
| Depreciation and amortization | 14.81M USD | 8.99M USD | 16.73M USD | 10.38M USD | 8.59M USD |
| Operating income | −555.34M USD | −487.34M USD | −196.7M USD | −340.74M USD | −295.75M USD |
| Net income | −512.54M USD | −422.77M USD | −145.22M USD | −325.99M USD | −290.58M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$33.67
80.44% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI102.22M0.00%2.3T USD0.03%$379.39-0.43%
iShares Russell 2000 ETFIWM74.11M0.09%78.56B USD0.19%$277.6-0.04%
Vanguard Morningstar Small-Cap ETFVB73.7M0.04%185.3B USD0.03%$287.61+0.22%
State Street SPDR S&P Biotech ETFXBI60.17M0.60%10.08B USD0.35%$149.36-0.58%
Vanguard Morningstar Small-Cap Growth ETFVBK42.44M0.09%44.7B USD0.05%$340.57-0.49%
Vanguard Extended Market ETFVXF41.57M0.04%95.4B USD0.05%$232.98-0.22%
T. Rowe Capital Appreciation Equity ETFTCAF26.32M0.29%9.09B USD0.31%$43.15-0.69%
Dimensional - US Small Cap ETFDFAS22.36M0.07%33.66B USD0.31%$78.155+0.30%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
